Session Information
-
WCLC 2019
2019 World Conference on Lung Cancer
Conference Program for the 2019 World Conference on Lung Cancer in Barcelona, Spain
Presentation Date(s):- Sept 7 - 10, 2019
- Total Presentations: 2970
September 7 Sat
Sep 7 Sunday
September 8 Sun
Sep 8 Monday
September 9 Mon
Sep 9 Tuesday
September 10 Tue
Sep 10
-
+
OA02 - A New Vision of Targets and Strategies
- 10:30 - 12:00
- 9/08/2019
- Location: Seoul (2007)
- IASLC CME Accredited
- Type: Oral Session
- Track: Targeted Therapy
- Moderators:Frank Griesinger, Luis Paz-Ares
-
+
OA02.03 - The Third Generation EGFR Inhibitor (EGFR-TKI) HS-10296 in Advanced NSCLC Patients with Resistance to First Generation EGFR-TKI
10:50 - 11:00 | Presenter: Shun Lu | Author(s): Qiming Wang, Guojun Zhang, Xiaorong Dong, Cheng-Ta Yang, Yong Song, Gee-Chen Chang, You Lu, Hongming Pan, Chao-Hua Chiu, Zhehai Wang, Jifeng Feng, Jianying Zhou, Xingxiang Xu, Renhua Guo, Jianhua Chen, Haihua Yang, Yuan Chen, Zhuang Yu, Her-Shyong Shiah, Chin-Chou Wang, Nong Yang, Jian Fang, Ping Wang, Kai Wang, Yanping Hu, Jianxing He, Ziping Wang, Jianhua Shi, Shaoshui Chen, Ying Cheng, Wu-Chou Su, Te-Chun Hsia, Jiuwei Cui, yuping Sun, Chih-Hsin Yang
- Abstract
Loading...
-
+
P1.01 - Advanced NSCLC
- 09:45 - 18:00
- 9/08/2019
- Location: Exhibit Hall
- Type: Poster Viewing in the Exhibit Hall
- Track: Advanced NSCLC
-
+
P1.01-121 - Superior Outcomes of 1st Line EGFR TKI in Next-Generation Sequencing Identified Uncommon EGFR Exon 19delins Mutation Non-Small Cell Lung Cancer
09:45 - 09:45 | Presenter: Yongchang Zhang | Author(s): Nong Yang, Tao Jiang, Caicun Zhou
- Abstract
Loading... -
+
P1.01-22 - Investigation of Acquired Resistance for EGFR-TKI Plus Bevacizumab as 1st Line Treatment in Patients with EGFR Sensitive Mutant NSCLC
09:45 - 09:45 | Presenter: Yongchang Zhang | Author(s): Liang Zeng, Nong Yang, Tao Jiang, Caicun Zhou
- Abstract
Loading...
-
+
P2.14 - Targeted Therapy
- 10:15 - 18:15
- 9/09/2019
- Location: Exhibit Hall
- Type: Poster Viewing in the Exhibit Hall
- Track: Targeted Therapy
-
+
P2.14-51 - Dual ALK Fusion Partners as Poor Predictive Marker in First Line Crizotinib Treated ALK Rearranged Non-Small Cell Lung Cancer
10:15 - 10:15 | Presenter: Yongchang Zhang | Author(s): Liang Zeng, Nong Yang, Tao Jiang, Caicun Zhou
- Abstract
Loading...